zum Inhalt springen

Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    Biodegradable core-multishell nanocarrier:
    topical tacrolimus delivery for treatment of dermatitis (2022)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Radbruch, Moritz (WE 12)
    Pischon, Hannah (WE 12)
    Du, Fang
    Haag, Rainer
    Schumacher, Fabian
    Kleuser, Burkhard
    Mundhenk, Lars (WE 12)
    Gruber, Achim D. (WE 12)
    Quelle
    Journal of controlled release
    Bandzählung: 349
    Seiten: 917 – 928
    ISSN: 1873-4995
    Sprache
    Englisch
    Verweise
    URL (Volltext): https://www.sciencedirect.com/science/article/abs/pii/S0168365922004448
    DOI: 10.1016/j.jconrel.2022.07.025
    Pubmed: 35905785
    Kontakt
    Institut für Tierpathologie

    Robert-von-Ostertag-Str. 15
    14163 Berlin
    +49 30 838 62450
    pathologie@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    Two challenges in topical drug delivery to the skin include solubilizing hydrophobic drugs in water-based formulations and increasing drug penetration into the skin. Polymeric core-multishell nanocarrier (CMS), particularly the novel biodegradable CMS (bCMS = hPG-PCL1.1K-mPEG2k-CMS) have shown both advantages on excised skin ex vivo. Here, we investigated topical delivery of tacrolimus (TAC; > 500 g/mol) by bCMS in a hydrogel on an oxazolone-induced model of dermatitis in vivo. As expected, bCMS successfully delivered TAC into the skin. However, in vivo they did not increase, but decrease TAC penetration through the stratum corneum compared to ointment. Differences in the resulting mean concentrations were mostly non-significant in the skin (epidermis: 35.7 ± 20.9 ng/cm2 for bCMS vs. 92.6 ± 62.7 ng/cm2 for ointment; dermis: 76.8 ± 26.8 ng/cm2vs 118.2 ± 50.4 ng/cm2), but highly significant in blood (plasma: 1.1 ± 0.4 ng/ml vs 11.3 ± 9.3 ng/ml; erythrocytes: 0.5 ± 0.2 ng/ml vs 3.4 ± 2.4 ng/ml) and liver (0.01 ± 0.01 ng/mg vs 0.03 ± 0.01 ng/mg). bCMS were detected in the stratum corneum but not in viable skin or beyond. The therapeutic efficacy of TAC delivered by bCMS was equivalent to that of standard TAC ointment. Our results suggest that bCMS may be a promising carrier for the topical delivery of TAC. The quantitative difference to previous results should be interpreted in light of structural differences between murine and human skin, but highlights the need as well as potential methods to develop more a complex ex vivo analysis on human skin to ensure quantitative predictive value.